Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Marine Fidelle et al.|Science|2017Cited by 5.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaDavid H. Henry, Howard Yeh, Luís Costa et al.|Journal of Clinical Oncology|2011Cited by 1.3k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone diseaseIngo Diel, Ada Braun, Jean‐Jacques Body et al.|European Journal of Cancer|2015Cited by 53
Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 ImmunotherapySarah Porte, Bruno Martin, Alexandra Audemard‐Verger et al.|Cancer Immunology Research|2024Cited by 11